Trial Profile
Dopamine D2/3- and μ-opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2015
Price :
$35
*
At a glance
- Drugs Amisulpride (Primary) ; Naltrexone (Primary)
- Indications Drug dependence
- Focus Therapeutic Use
- 25 Sep 2015 New trial record